• Carrier platform diversification unified as a modular nanomedicine strategy: polymer micelles, PEGylated nanospheres, SLN, and nanocapsules enabling loading, controlled release, and targeted delivery across oncologic and peptide therapeutics [1], [2], [6], [9], [15], [16], [17].

• Nanocarriers consistently target and traverse physiological barriers, using surface modifications and carrier choices to ferry drugs across the blood-brain barrier and intestinal epithelium (e.g., polysorbate-coated particles and mucoadhesive polymers) [4], [5], [10], [19].

• Oral and mucosal peptide delivery is a key focus, leveraging mucoadhesive polymers, chitosan-PEO nanoparticles, and nanocapsules to protect peptides and enhance intestinal uptake; insulin and peptides illustrate translational routes [7], [10], [12], [13], [17].

• Surface engineering and size control promote long circulation and tumor targeting; PEGylation and block copolymer micelles yield enhanced tumor accumulation and target-specific pharmacokinetics [2], [11], [14], [15], [16], [18].

• Engineering and characterization of specialized colloidal carriers addresses production, sterilization, and triggering release, advancing robust nanocarrier design [6], [9], [15], [17], [20].